Cinod 5 Tablet (Cilnidipine)

Description

Cinod 5 Tablet (Cilnidipine) — Complete Clinical and Patient Information Guide

Product Overview

Cinod 5 Tablet (Cilnidipine) contains Cilnidipine 5mg as its active pharmaceutical ingredient, belonging to the fourth-generation dual N+L-type calcium channel blocker (dihydropyridine CCB). It is clinically indicated for hypertension — monotherapy or as part of combination antihypertensive therapy; particularly advantageous in hypertension with CKD, diabetic nephropathy, or proteinuria. This guide has been prepared in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established cardiovascular clinical guidelines.

Cinod 5mg contains Cilnidipine 5mg — a fourth-generation dual N+L-type calcium channel blocker that represents a significant pharmacological advance over conventional dihydropyridine CCBs. The N-type channel-blocking component provides cilnidipine with three clinically meaningful advantages: reduced reflex tachycardia (compared to amlodipine), renoprotection through reduced glomerular hyperfiltration, and significantly less peripheral oedema. These properties make cilnidipine particularly valuable for hypertensive patients with CKD, diabetes, proteinuria, or who have experienced significant ankle oedema with conventional CCBs. 5mg

About Cinod 5mg and Its Active Ingredient

Cilnidipine 5mg is the pharmacologically active compound in Cinod 5mg. Cardiovascular medications are among the most safety-critical drugs prescribed — interactions with other heart medications, anticoagulants, and antihypertensives can have life-threatening consequences, and abrupt discontinuation of certain cardiac drugs (beta-blockers, anticoagulants) without medical guidance can precipitate dangerous rebound phenomena. All cardiovascular pharmacotherapy decisions require specialist or physician oversight, with regular monitoring and dose optimisation based on clinical response, ECG findings, blood pressure recordings, and relevant biochemical parameters.

Mechanism of Action

Cilnidipine is a unique fourth-generation dihydropyridine calcium channel blocker (CCB) that differentiates itself from other CCBs through its dual inhibition of both L-type (Long-lasting) and N-type (Neuronal) voltage-gated calcium channels. This dual-channel pharmacology gives cilnidipine a distinctive clinical profile. L-type calcium channel blockade in vascular smooth muscle cells reduces intracellular calcium, causing arterial vasodilation and consequent blood pressure reduction — the mechanism shared with amlodipine, nifedipine, and all other dihydropyridine CCBs. The additional N-type calcium channel blockade in sympathetic nerve terminals is unique to cilnidipine: N-type channels control calcium-dependent noradrenaline release from postganglionic sympathetic neurons innervating resistance vessels. By blocking N-type channels at sympathetic nerve endings in the kidney, mesenteric circulation, and peripheral vasculature, cilnidipine reduces neurally-mediated vasoconstriction and — critically — inhibits renal sympathetic activity and noradrenaline-mediated afferent arteriolar constriction. This mechanism explains cilnidipine’s key advantages over conventional CCBs: markedly reduced reflex sympathetic activation (less tachycardia and palpitations compared to other dihydropyridines), superior reduction in glomerular filtration pressure (renoprotective effect independent of blood pressure reduction), and reduced sympathetically-mediated peripheral oedema (ankle swelling is significantly less common with cilnidipine than amlodipine). The N-type calcium channel blockade also reduces sympathetically-mediated proteinuria in diabetic and hypertensive renal disease, making cilnidipine a preferred antihypertensive in patients with CKD and proteinuria.

A clear understanding of the pharmacological mechanism helps explain the clinical requirements: why timing, dose titration, monitoring, drug interactions, and contraindications exist. Healthcare providers use mechanistic knowledge to individualise therapy, anticipate interactions, and monitor for treatment response and toxicity.

Clinical Indications

Cinod 5 Tablet (Cilnidipine) is clinically indicated for:

• Primary indication: hypertension — monotherapy or as part of combination antihypertensive therapy; particularly advantageous in hypertension with CKD, diabetic nephropathy, or proteinuria
• Specialist assessment required: Cardiovascular drug therapy must be initiated and monitored by a qualified cardiologist, physician, or specialist. Self-diagnosis and self-treatment of cardiac conditions is dangerous and may delay life-saving treatment.

Dosage and Administration

Adults: cilnidipine 5mg once daily with food (food significantly improves absorption — take with meals consistently). Starting dose: 5mg once daily; titrate to 10mg, 20mg as needed based on blood pressure response at 4-week intervals. Maximum dose: 20–40mg/day. 5mg

Never adjust the dose or stop cardiovascular medications without consulting your prescribing physician. Abrupt withdrawal of beta-blockers, anticoagulants, and anti-anginal drugs can cause dangerous rebound phenomena including angina exacerbation, myocardial infarction, and thromboembolic events.

Who Should Use Cinod 5mg

Cinod 5mg is indicated for adult patients in whom the relevant cardiovascular condition has been confirmed by clinical assessment and appropriate investigations (ECG, echocardiogram, cardiac biomarkers, blood pressure recording, coagulation studies as applicable) and in whom this specific pharmacological approach has been determined to be clinically appropriate after benefit-risk assessment.

Contraindications

Hypersensitivity to cilnidipine or other dihydropyridines. Severe hypotension. Cardiogenic shock. Unstable angina. Severe hepatic impairment.

Drug Interactions

Other antihypertensives: additive BP lowering — monitor. CYP3A4 inhibitors (ketoconazole, ritonavir, grapefruit juice): increase cilnidipine plasma levels — use with caution and monitor BP. Beta-blockers: concurrent use with cilnidipine can cause excessive bradycardia or hypotension in susceptible patients but is often used deliberately for additive antihypertensive and cardioprotective effects.

Cardiovascular drugs have numerous clinically significant, potentially dangerous drug interactions. A comprehensive medication review by a cardiologist or clinical pharmacist is essential before initiating or changing any cardiac medication. Patients must inform all healthcare providers (including dentists, surgeons, and emergency physicians) of all their cardiovascular medications.

Adverse Effects

Very common: Peripheral oedema (ankle swelling) — caused by arteriolar dilation increasing capillary hydrostatic pressure; significantly less common with cilnidipine than amlodipine due to N-type channel-mediated venous tone preservation. Headache and flushing from vasodilation. Common: Dizziness, palpitations, fatigue. Uncommon: Nausea, gingival hyperplasia with long-term use. Rare: Severe hypotension (especially with first dose in volume-depleted patients).

Cilnidipine-specific advantages: Significantly less peripheral oedema than conventional dihydropyridine CCBs (ankle swelling in ~5–8% vs 15–20% with amlodipine). Substantially less reflex tachycardia due to N-type sympathetic blockade. Renoprotective effect in CKD and diabetic nephropathy through reduced glomerular hyperfiltration.

Special Population Considerations

Renal protection: Cilnidipine provides renal protective benefits beyond blood pressure reduction — N-type calcium channel blockade in renal sympathetic nerves reduces afferent arteriolar constriction and glomerular hyperfiltration. Clinical studies demonstrate reductions in urinary albumin-to-creatinine ratio with cilnidipine independent of blood pressure changes. Food interaction: Take consistently with meals — food approximately doubles cilnidipine bioavailability. Elderly: Start at 5mg and titrate carefully — elderly patients may be more sensitive to vasodilatory effects.

Storage and Handling

Store Cinod 5mg at room temperature (15–25°C) in a dry location away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Do not use beyond the printed expiry date. Nitroglycerin preparations require special storage in airtight glass containers away from heat — plastic and light degrade GTN. Enoxaparin: store at room temperature; do not freeze.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Do not use after the expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember unless it is nearly time for the next scheduled dose. Never double-dose. Do not stop beta-blockers, anticoagulants, or anti-anginal medications abruptly without medical advice.

Q: Why is cilnidipine considered better than amlodipine for patients with kidney disease?
A: Cilnidipine’s N-type calcium channel blockade in renal sympathetic nerve terminals reduces noradrenaline release in the kidney, decreasing afferent arteriolar tone and glomerular filtration pressure. This reduces proteinuria and slows CKD progression beyond what blood pressure reduction alone achieves. Multiple clinical studies have demonstrated superior antiproteinuric effect with cilnidipine compared to amlodipine at equivalent blood pressure reduction — making it the preferred CCB for hypertensive patients with diabetic or non-diabetic CKD.

Evidence Base and Cardiovascular Guidelines

The active ingredient in Cinod 5mg has been evaluated in landmark randomised controlled trials and is supported by major international cardiovascular guidelines including those from the European Society of Cardiology (ESC), American College of Cardiology/American Heart Association (ACC/AHA), American Heart Association, National Institute for Health and Care Excellence (NICE), and relevant national cardiovascular specialist bodies. These guidelines represent evidence-based consensus on optimal pharmacological management of cardiovascular conditions and are regularly updated as new clinical evidence emerges.

Cardiovascular disease management has undergone transformative advances over the past three decades — from the landmark MERIT-HF, CAPRICORN, and EMPHASIS-HF trials establishing guideline-directed medical therapy for heart failure, to the COURAGE trial for stable angina, EINSTEIN for anticoagulation, and ADVANCE-HF for newer agents. Patients benefit most when their individual pharmacotherapy aligns with current evidence-based guidelines.

Patient Counselling Points

• Never stop abruptly: Beta-blockers, anti-anginal drugs, and anticoagulants must never be stopped suddenly without medical guidance — abrupt withdrawal can trigger angina rebound, myocardial infarction, arrhythmia, or thromboembolic events.
• Carry a medication list: All patients on cardiovascular drugs should carry a current medication list for any medical encounter — including surgical, dental, and emergency care. Drug interactions in cardiovascular patients can be life-threatening.
• Regular monitoring: Blood pressure, ECG, renal function, electrolytes (for diuretics), INR (for warfarin), platelet count (for heparins), and cardiac biomarkers as appropriate should be monitored at intervals determined by your cardiologist.
• Lifestyle integration: Pharmacotherapy delivers best results alongside appropriate lifestyle modification: Mediterranean diet, regular aerobic exercise, smoking cessation, moderate alcohol, sodium restriction for hypertension and heart failure.

Cardiovascular Disease Context and Clinical Management Principles

Cardiovascular disease (CVD) remains the leading cause of death globally, responsible for approximately 18 million deaths annually — representing 32% of all global mortality. Coronary artery disease, heart failure, hypertension, stroke, and peripheral arterial disease collectively impose an enormous burden of mortality, morbidity, and reduced quality of life worldwide. The last five decades have witnessed transformative advances in cardiovascular pharmacotherapy — from the introduction of beta-blockers and ACE inhibitors, through the development of statins and thrombolytics, to the current era of guideline-directed medical therapy with proven mortality-reducing agents for heart failure, and novel anticoagulants revolutionising stroke prevention in atrial fibrillation.

Effective cardiovascular disease management requires integration of pharmacological therapy with lifestyle modification (Mediterranean diet, regular aerobic exercise, smoking cessation, alcohol moderation, sodium restriction), risk factor control (blood pressure, lipid management, glycaemic control, weight management), and appropriate interventional or surgical procedures where indicated. Pharmacotherapy alone, without lifestyle integration and risk factor management, provides suboptimal benefit — drugs and lifestyle modification are synergistic, not alternative, approaches.

Hypertension: The Silent Cardiovascular Risk Factor

Hypertension affects approximately 1.28 billion adults worldwide, yet only 21% of hypertensive adults have their blood pressure adequately controlled. Uncontrolled hypertension is the leading modifiable risk factor for stroke, coronary artery disease, heart failure, renal failure, and peripheral arterial disease. The relationship between blood pressure and cardiovascular risk is continuous — even high-normal blood pressure (130–139/85–89 mmHg) carries increased cardiovascular risk compared to optimal levels.

Current international guidelines (ESC/ESH, ACC/AHA, NICE) recommend initial drug therapy for hypertension with one of three evidence-based drug classes: angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs); calcium channel blockers (CCBs); or thiazide/thiazide-like diuretics. Most patients with stage 2 hypertension (≥160/100 mmHg) require combination therapy from initial diagnosis. Fixed-dose combination tablets — such as those in this product range — improve adherence and simplify therapy for patients requiring multiple agents.

Angina Pectoris: Management Principles

Stable angina pectoris affects over 110 million people globally and represents myocardial ischaemia occurring predictably with exertion or emotional stress, relieved by rest or sublingual nitroglycerin within minutes. The management goal is threefold: symptom relief, prevention of disease progression and MI, and improvement of quality of life. First-line symptomatic therapy uses beta-blockers and/or calcium channel blockers as rate-limiting or vasodilatory agents; long-acting nitrates or nicorandil are added when first-line therapy is insufficient. For resistant symptoms, trimetazidine or ivabradine (when HR remains elevated) provide additional anti-anginal mechanisms. When pharmacological therapy fails to control symptoms adequately, coronary revascularisation (PCI or CABG) should be considered.

Quality Standards and Evidence Base

The active ingredients in products in this range have been evaluated in landmark randomised controlled trials that form the foundation of evidence-based cardiovascular medicine: MERIT-HF (metoprolol succinate in HFrEF), CAPRICORN and COPERNICUS (carvedilol in post-MI LV dysfunction and HFrEF), BEAUTIFUL (ivabradine in stable CAD), SIGNIFY (ivabradine in stable angina), EINSTEIN (enoxaparin in VTE), EXTRACT-TIMI 25 (enoxaparin in STEMI), and IONA (nicorandil in stable angina). Major cardiovascular guidelines from the ESC, ACC/AHA, and NICE incorporate these drugs into evidence-based treatment algorithms based on the totality of this evidence.

Products are manufactured in compliance with Good Manufacturing Practice (GMP) standards required by national and international pharmaceutical regulatory authorities, ensuring consistent quality, identity, strength, and purity. Patients should always obtain prescription cardiovascular medications from licensed pharmacies with valid prescriptions to ensure receipt of authentic, properly stored, quality-assured products.

Important Medical Disclaimer

This product information guide is provided for general educational purposes only, prepared in accordance with YMYL (Your Money Your Life) content standards. All information draws on regulatory prescribing information, peer-reviewed cardiology literature, and established clinical guidelines. It does not replace professional medical advice, diagnosis, or treatment from a qualified cardiologist, physician, or pharmacist. Cardiovascular drug therapy decisions must be individualised by a licensed healthcare provider with full knowledge of the patient’s cardiac status, comorbidities, and concurrent medications. Self-diagnosis and self-treatment of cardiovascular conditions can be dangerous and life-threatening. Always consult a qualified cardiologist or physician before starting, changing, or stopping any cardiovascular medication.